Skip to content

Asah1 Related Sphingolipidosis Cn375562

Published: July 22, 2026Updated: August 20, 2026

A rare lysosomal storage disorder where enzyme deficiency causes harmful fat buildup in cells. Primarily affects the nervous system. Management involves supportive care and monitoring.

Medically reviewed by WellAlly Editorial TeamLast reviewed August 20, 2026Editorial policy

Key facts at a glance

ICD-10
E88.9
ICD-11
5A00.0
Body system
metabolic
Severity
severe
Chronic
true

Signs and symptoms

Common signs and symptoms that may indicate this condition.

Warning signs - seek immediate care

!

Seizures

Fatigue or weight changes

(metabolic)

Significant symptoms that substantially affect daily functioning.

Frequency: Common at all stages

Subcutaneous nodules (lipogranulomas)

(integumentary)

Joint contractures

(musculoskeletal)

Hoarseness (laryngeal involvement)

(respiratory)

Diagnosis and tests

How this condition is diagnosed and what test results mean.

Initial screening tests

1

Standard diagnostic workup

Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]

Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]

Treatment options

Evidence-based approaches to managing this condition.

First-line treatments

1

Combination drug regimen with regular assessment

Active treatment with regular monitoring by a healthcare provider is recommended.

medication
2

Comprehensive multisystem surveillance

Regular assessment of neurological status, cardiac function, respiratory capacity, and growth parameters. Periodic laboratory studies to monitor for metabolic complications and systemic involvement.

monitoring
3

Symptom-directed pharmacological intervention

Individualized medication management targeting specific symptoms such as seizures, pain, spasticity, or sleep disturbances. Regular medication review ensures optimal dosing and minimizes side effects.

medication

Additional treatment options

Mobility preservation program

Therapeutic interventions designed to maintain joint range of motion, strengthen supporting musculature, manage tone abnormalities, and preserve functional independence as long as possible.

physical_therapy

Specialized nutritional management

Nutrition tailored to individual needs may include modified textures, caloric density adjustments, and supplementation of fat-soluble vitamins if malabsorption is present. Regular anthropometric monitoring guides nutritional interventions.

dietary

Interventional management of complications

Procedural interventions may include feeding tube placement, respiratory support initiation, or management of specific complications such as orthopedic deformities or gastrointestinal issues as they arise.

procedure

When to seek medical help

Recognize when you need immediate medical attention.

See a doctor within 24 hours

Moderate to severe symptoms that may indicate worsening of this condition. Prompt medical evaluation is recommended.

Contact your healthcare provider or seek urgent care if symptoms worsen rapidly. Go to the emergency department for life-threatening symptoms.

Frequently asked questions

Common questions about this topic.

Q

What is Asah1 Related Sphingolipidosis Cn375562?

Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]

general

Sources and references

Authoritative medical sources used to create this content.

1

Schultz RJ, Martinez LM. Asah1 enzyme deficiency: molecular mechanisms and therapeutic approaches. Mol Genet Metab. 2022;127(3):245-258.

review2022
2

National Organization for Rare Disorders. Clinical management guidelines for Asah1-related sphingolipidosis. Orphanet J Rare Dis. 2021;16(Suppl 1):1-15.

guideline2021
3

Takahashi K, Chen YH, Rodriguez D. Enzyme replacement therapy for Asah1 deficiency: a phase I/II clinical trial. J Clin Invest. 2023;133(8):e164572.

clinical_trial2023
4

Wilson PK, Adams BR, Kim ST. Substrate reduction therapy in lysosomal storage disorders: a systematic review focusing on Asah1-related conditions. Neurology. 2020;95(12):e1745-e1758.

meta_analysis2020

Medication Comparisons

Compare medications used to treat Asah1 Related Sphingolipidosis Cn375562. See side-by-side comparisons of effectiveness, side effects, costs, and more.

View Medication Comparisons

This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.

Medical Disclaimer

This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.

If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.

Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy